MRKMerck Sharp & Dohme LLCFinished
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Hodgkin's Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 66 (final count)
- Started
- Jun 7, 2021
- Main results expected
- Dec 14, 2023
- Fully finished
- Oct 13, 2025
- Results posted
- Feb 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator
Measured over: Up to approximately 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04875195 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC